文献速递浆细胞疾病

新诊断多发性骨髓瘤伴染色体1q异常的临床特征与治疗结局

Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities.
PubMed 文献 · Blood Adv · 2020-01-01

该研究纳入2005至2018年Mayo Clinic诊断的1376例多发性骨髓瘤患者,诊断时荧光原位杂交检测含+1q探针。391例(28%)存在1q增益,与贫血、高钙血症、高肿瘤负荷、ISS 3期、高危易位及13号染色体异常相关。+1q与至下次治疗时间缩短(19.9 vs 27.7个月,P<.001)及独立降低总生存相关(多因素RR 1.5,P<.001)。

要点

  • 1q增益见于28%新诊断多发性骨髓瘤患者,与贫血、高钙血症、高肿瘤负荷、ISS 3期、高危易位及13号染色体异常相关。
  • 1q增益者至下次治疗时间较无1q增益者缩短(19.9 vs 27.7个月,P<.001)。
  • 多因素分析中1q增益独立降低总生存(RR 1.5,P<.001),且在新型治疗和移植背景下仍存在。

核心结论

  • 1q增益与高肿瘤负荷、晚期疾病阶段和高危易位相关,且独立降低总生存,即使在新型治疗和移植背景下仍存在。

研究设计与样本

  • 研究纳入2005至2018年Mayo Clinic诊断的1376例多发性骨髓瘤患者,诊断时接受含+1q探针的荧光原位杂交检测。

主要发现

  • 391例(28%)存在1q增益,与贫血、高钙血症、高肿瘤负荷、ISS 3期、高危易位及13号染色体异常相关。
  • 对蛋白酶体抑制剂、免疫调节药物或蛋白酶体抑制剂联合免疫调节药物为基础诱导治疗的总缓解或更深缓解无差异。
  • 1q增益者至下次治疗时间较无1q增益者缩短(19.9 vs 27.7个月;P<.001)。
  • 单因素分析中1q增益与死亡风险增加相关(风险比[RR] 1.9;P<.001),所有治疗组均见总生存降低。
  • 多因素分析纳入其他高危细胞遗传学异常、ISS 3期和年龄≥70岁后,1q增益独立降低总生存(RR 1.5;P<.001)。

关键数值与推荐

  • 1q增益定义为荧光原位杂交检测含+1q探针显示1q拷贝数增加,见于391/1376例(28%)。
  • 至下次治疗时间:1q增益组19.9个月 vs 无1q增益组27.7个月(P<.001)。
  • 单因素死亡风险比:+1q vs 无+1q,RR 1.9(P<.001)。
  • 多因素总生存风险比:+1q vs 无+1q,RR 1.5(P<.001),模型纳入其他高危细胞遗传学异常、ISS 3期和年龄≥70岁。
  • 1q增益超过1个拷贝 vs 1个拷贝的总生存:4.9年 vs 4.3年(P=.21)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A gain in chromosome 1q (+1q) is among the most common cytogenetic abnormalities in multiple myeloma (MM). It is unclear whether +1q is independently associated with decreased overall survival (OS). The objective of this study was to evaluate the impact of +1q on clinical characteristics, treatment response, and survival outcomes. We included 1376 Mayo Clinic patients diagnosed with MM from 2005 to 2018 who underwent fluorescence in situ hybridization testing at diagnosis with a panel including the +1q probe. A gain in 1q was found in 391 patients (28%) and was associated with anemia, hypercalcemia, high tumor burden, International Staging System (ISS) stage 3, high-risk (HR) translocations, and chromosome 13 abnormalities. There was no difference in overall response or deeper responses to proteasome inhibitor (PI)-, immunomodulatory drug (iMiD)-, or PI plus IMiD-based induction. Time to next treatment was shorter in patients with +1q compared with those without +1q (19.9 vs 27.7 months; P < .001). On univariate analysis, +1q was associated with increased risk of death (risk ratio [RR], 1.9; P < .001), and decreased OS was seen in all treatment groups. +1q was independently associated with decreased OS on multivariate analysis when other HR cytogenetic abnormalities, ISS stage 3, and age ≥70 years were included (RR, 1.5; P < .001). Gain of >1 copy of 1q was not associated with worse OS compared with gain of 1 copy (4.9 vs 4.3 years; P = .21). +1q was associated with high tumor burden, advanced disease stage, and HR translocations. It is independently associated with decreased OS, even in the setting of novel therapy and transplant.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Abdallah N, Greipp P, Kapoor P, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020. PMID: 32750129. doi:10.1182/bloodadvances.2020002218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。